Teh Winter Surge and the RSV Threat

Chile’s healthcare system braces each winter for a predictable surge in respiratory illnesses. hospitals and emergency rooms often face immense pressure due to the increased circulation of viruses like influenza, COVID-19, and, most notably, Respiratory Syncytial Virus (RSV). While vaccines exist to combat RSV in vulnerable populations,their integration into the national immunization program remains a point of contention.

Approved but Not Implemented: The RSV Vaccine Dilemma

Despite the Chilean Institute of Public Health (ISP) approving RSV vaccines for both pregnant women and older adults in 2024, these preventative measures have yet to be incorporated into the Ministry of Health’s official strategy. this decision raises questions, especially considering the potential to mitigate severe illness and hospitalizations in these high-risk groups.

Expert Recommendations and Hesitations

In November 2023, the Advisory Committee on Vaccines and Immunization Strategies (Cavei), a body advising the Ministry of Health, recommended RSV vaccination primarily for older adults at high risk of severe complications. While Cavei acknowledged the vaccine’s effectiveness in preventing RSV-related respiratory infections,it stopped short of advocating for its inclusion in the national immunization calendar. This cautious approach contrasts with the proactive strategies adopted by other Latin American nations.

The health authorization of the RSV vaccine by the Institute of public Health (ISP) represents a critically important advance.
Elizabeth López, Chief of the National Immunizations Program (PNI)

Pharmaceutical Efforts to Bridge the Gap

Following the ISP’s approval, pharmaceutical companies like Pfizer and GSK have actively engaged with Chilean health authorities to advocate for the vaccine’s inclusion in the national immunization strategy. These efforts included meetings with key officials to present vaccine profiles and address any concerns regarding prioritization and implementation, particularly for the elderly population.

From Pfizer we maintain a permanent dialog with the authorities to ensure that they can have complete and updated information regarding the vaccines that our company has available. At the Latin American level there are already countries that have incorporated or are incorporating this vaccine into their immunization programs.
Ana María Karachón, Director of public Affairs of Pfizer Andino

Current Strategies: A Focus on Infants

Currently, Chile’s national immunization program focuses on protecting infants through the administration of the Nirsevimab monoclonal antibody, starting in March.This strategy has demonstrated success,leading to a significant decrease in pediatric hospitalizations and,notably,zero RSV-related deaths in children under one year old in 2024. However, experts argue that this approach could be further enhanced by vaccinating pregnant women, providing passive immunity to their newborns.

A Call for Extensive Protection

Dr. Jaime Rodríguez, Chief of Child Infectology at the German Clinic and former president of Cavei, emphasizes the potential benefits of a multi-pronged approach.He suggests that the Pfizer vaccine, administered during pregnancy, could complement the existing antibody strategy for infants. moreover, he advocates for the widespread availability of RSV vaccines for adults, offering crucial protection to another vulnerable demographic.

Looking Ahead: private Sector Access and Future Considerations

While the RSV vaccine remains absent from the national immunization program,it is indeed becoming increasingly available through private vaccination channels. The National Immunizations Program (PNI) continues to evaluate the incorporation of new vaccines and immunization schemes, leaving the door open for potential changes in the future. The ongoing debate highlights the need for a comprehensive strategy that protects all vulnerable populations from the potentially severe consequences of RSV infection.The keywords are: RSV vaccine, immunization strategy, Chile, vulnerable populations, pregnant women, older adults, respiratory syncytial virus.